摘要
目的:探讨RhC、c、E及e抗原相合在输血安全中的应用效果及临床价值。方法:取2015年4月-2017年7月医院收治的上消化道出血、失血性休克需要输血治疗的患者120例,采用凝聚胺介质法及抗人球蛋白法对患者RhC、c、E及e抗原进行检测,明确患者血型,密切观察患者生命体征,输注2个单位红细胞悬液后,观察RhC、c、E及e抗原相同表型(观察组)与RhC、c、E及e抗原不同表型输血组(对照组)输血前、后血红蛋白、血细胞比容及输血不良反应情况。结果:两组输血前血红蛋白、血细胞比容水平比较差异无统计学意义(P>0.05);输血后血红蛋白、血细胞比容水平比较差异亦无统计学意义(P>0.05);观察组输血后不良反应发生率为5.00%,与对照组13.33%比较,差异有统计学意义(P<0.05)。结论:输血患者在输血前进行Rh型系统RhC、c、E及e抗原常规检测有助于减少输血引起的免疫反应,提高输血安全,值得推广应用。
Objective： To investigate the effect and clinical efficacy of RhC, c, E and e antigen consistency in transfusion safety.Method： Among 120 inpatients of upper gastrointestinal hemorrhage and hemorrhagic shock from April 2015 to July 2017, polybrene method and Coomb＇s test were used to screen for RhC, c, E and e blood group antigens.The experimental group was consisted of RhC, c, E and e antigens of the same phenotype, whereas the control group had C, c, E and e antigens of different pbenotypes.After infusion of two units of red blood cell suspension and close vital signs monitoring, hemoglobin, hematocrit and blood transfusion adverse reactions were compared between the experimental group and the control group before and after blood transfusion.Result： Hemoglobin and hematocrit levels had no significant difference between the two groups prior to and post blood transfusion（P〉0.05）, the experimental group has 5.00% post-transfusion adverse reaction rate, compared to 13.33% of the control group, there was significant difference（P〈0.05）.Conclusion： Routine screening of Rh, RhC, c, E and e antigens prior to transfusion is indicative for adverse immune response minimization.
作者
陈惠红
吕兆祺
CHEN Huihong, LYU Zhaoqi(The Fifth Affiliated Hospital of Guangzhou Medical University , Guangzhou510700, Chin)
出处
《中外医学研究》
2018年第8期73-74,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
